Get started
Author

Dipmoy Nath

Observed name: Nath Dipmoy
ORCID: 0009-0002-6017-4726
Observed ORCID: 0009-0002-6017-4726
OpenAlex ID: A5070552158
Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm
2016 · Yue Yang, Hajime Akada, et al. · Blood · 104
Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models
2021 · Avik Dutta, Dipmoy Nath, et al. · Leukemia · 34
The PIM Kinase Inhibitor TP-3654 in Combination with Ruxolitinib Exhibits Marked Improvement of Myelofibrosis in Murine Models
2018 · Dipmoy Nath, Avik Dutta, et al. · Blood · 5
The NF-KB Inhibitor DMAPT in Combination with Ruxolitinib Displays Efficacy in Jak2V617F Knock-in Mouse Model of Myeloproliferative Neoplasms
2018 · Yue Yang, Dipmoy Nath, et al. · Blood · 4
The CDK6 Inhibitor Palbociclib in Combination with Ruxolitinib Remarkably Improves Myelofibrosis in Murine Models
2019 · Golam Mohi, Avik Dutta, et al. · Blood · 2
Abstract 1874: The PIM kinase inhibitor TP-3654 demonstrates efficacy in a murine model of myelofibrosis
2018 · Avik Dutta, Dipmoy Nath, et al. · Cancer Research · 2
Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments (TMEs) into distinct Pro-inflammatory tmes
2025 · Muharrem Muftuoglu, Sandeep Singh, et al. · Blood · 1
PDF
Engineered IL7/IL15 secreting iPSC-derived mesenchymal stromal cells reprogram the immunosuppressive tumor microenvironment and potentiate antitumor immunity
2025 · Sandeep Singh, Andrea Bedoy, et al. · Blood · 1
Loss of EZH2 Inhibits Erythropoiesis and Accelerates the Development of Myelofibrosis in Jak2V617F Knock-in Mice
2014 · Yue Yang, Hajime Akada, et al. · Blood · 1
IL7-IL15 fusion cytokine (fusokine)–secreting iPSC-derived mesenchymal stromal cells to convert immunosuppressive into highly immune-activated tumor microenvironments (TMEs), potentiate antitumor immunity, and synergize with PD-1 inhibition in ovarian cancer.
2026 · Michael Andreeff, Sandeep Singh, et al. · Journal of Clinical Oncology
Abstract 7953: Engineered IL7/IL15 secreting iPSC-derived mesenchymal stromal cells convert the immunosuppressive into immune-activated tumor microenvironments (TME) and potentiate antitumor immunity
2026 · Michael Andreeff, Sandeep Singh, et al. · Cancer Research
Abstract PR001: Gene-modified iPS-derived MSC restore a ‘Hot’ immune microenvironment in high-grade serous ovarian cancer
2025 · Muharrem Muftuoglu, Sandeep Singh, et al. · Cancer Research
Engineering iPSC-derived mesenchymal stem cells (i MSCs) to secrete IL-7/IL-15 for modulation of the tumor microenvironment in a "cold" ovarian tumor model.
2025 · Sandeep Singh, Andrea D. Bedoy, et al. · Journal of Clinical Oncology
Abstract 3473: iPS-derived MSC secreting IL7 and IL15 exert immune mediated anti-tumor activities
2025 · Sandeep Singh, Andrea Bedoy, et al. · Cancer Research
Data from CDK6 Is a Therapeutic Target in Myelofibrosis
2023 · Avik Dutta, Dipmoy Nath, et al.
Supplementary Data from CDK6 Is a Therapeutic Target in Myelofibrosis
2023 · Avik Dutta, Dipmoy Nath, et al.
Supplementary Data from CDK6 Is a Therapeutic Target in Myelofibrosis
2023 · Avik Dutta, Dipmoy Nath, et al.
PDF
Data from CDK6 Is a Therapeutic Target in Myelofibrosis
2023 · Avik Dutta, Dipmoy Nath, et al.
Abstract 5376: Requirement of TET2 in MLL-AF9 mediated leukemogenesis
2017 · Dipmoy Nath, Golam Mohi · Cancer Research
The Role of TET Methylcytosine Dioxygenase 2 in Myeloid Malignancies
2017 · Dipmoy Nath · SUNY Digital Repository Support (State University of New York System)
Works count: 20
Citation count: 154
H-index: 4
I10-index: 2
Year
Topic
Type